{"id":1068401,"date":"2023-03-31T00:42:44","date_gmt":"2023-03-31T04:42:44","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/sutro-biopharma-reports-full-year-2022-financial-results-business-highlights-and-select-anticipated-milestones\/"},"modified":"2024-08-18T11:46:46","modified_gmt":"2024-08-18T15:46:46","slug":"sutro-biopharma-reports-full-year-2022-financial-results-business-highlights-and-select-anticipated-milestones","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/sutro-biopharma-reports-full-year-2022-financial-results-business-highlights-and-select-anticipated-milestones.php","title":{"rendered":"Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones"},"content":{"rendered":"<p><![CDATA[- Sutro plans to initiate a Phase 2\/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quarter -]]><\/p>\n<p>Originally posted here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2023\/03\/30\/2638228\/0\/en\/Sutro-Biopharma-Reports-Full-Year-2022-Financial-Results-Business-Highlights-and-Select-Anticipated-Milestones.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones\">Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Originally posted here: Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/sutro-biopharma-reports-full-year-2022-financial-results-business-highlights-and-select-anticipated-milestones.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068401","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068401"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068401"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068401\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}